Dr. Naval Parikh participated as an investigator in a recent Napa Research study that has been featured in the New England Journal of Medicine on the fight against COVID-19..
POMPANO BEACH, Fla. (PRWEB) January 10, 2022
December 31, 2021, Dr. Naval Parikh participated as an investigator in a study that has been featured in the New England Journal of Medicine. The study that was released aimed to investigate a particular antibody’s effectiveness against COVID-19. As of today, sotrovimab is the only monoclonal antibody shown to be effective against the Omnicron variant.
The study revealed that sotrovimab, a medication with anti-viral properties was effective in lessening the severity of COVID-19. Moreover, sotrovimab displayed great promise in terms of preventing the progression of COVID-19 in high-risk patients.
Sotrovimab is essentially an antibody that the FDA has approved for emergency usage on COVID patients 12 or older. Dr. Parikh’s contribution to the recent study which has highlighted sotrovimab’s effects on COVID-19 has helped pave the way for more innovative treatment options.
One group of patients was given a placebo while the others received a single infusion of sotrovimab. The dose was 500 mg which resulted in fewer adverse events than patients from the control group. As such, sotrovimab has demonstrated potential as an antibody that can be used to treat COVID patients safely and successfully.
In addition to operating a primary care clinic in Florida, Dr. Parikh lends his valuable medical expertise to NAPA Research which helps spearhead efforts to research various treatments and therapies. His research serves to advance the field of medical science in a continuous effort to develop effective treatments. The treatments and therapies that are derived from his work at NAPA Research help make the world a brighter, healthier place.
The recent results from the study on the sotrovimab antibody offer hope for those looking for viable treatment options in the fight against COVID-19. As of today, sotrovimab is the only monoclonal antibody shown to be effective against the Omnicron variant.
About Naval Parikh:
Dr. Naval Parikh is a talented and compassionate doctor based in the South Florida area. His primary care practice allows him to help countless patients while contributing his profound medical knowledge and expertise to NAPA Research where he serves as the principal investigator in Pompano Beach, Florida.
Press release by Press release by South Florida Media.
Press Release By South Florida Media
Share article on social media or email: